Corbevax becomes the second vaccine to get approval for children aged 12-18


Biological E’s covid vaccine ‘Corbevax’ got approval for emergency use by Drugs Controller General of India (DCGI) on Monday. The Hyderabad-based pharmaceutical company’s vaccine is the third vaccine to get approved for children aged between 12-18 years after Zydus Cadila’s DNA shot ZyCoV-D and Bharat Biotech’s Covaxin. As of now, teens aged between 15-18 were receiving Bharat Biotech’s Covaxin shots. Corbevax vaccine had received a EUA (Emergency use authorization) via the Subject Expert Committee of Drugs Controller General of India (DCGI). EUA was only approved after reviewing the safety and immunogenicity data of a clinical study conducted in October 2021 by Biological E. 

“BE received the approval for restricted use in an emergency in adolescents aged 12 to 18 years based on interim results (of the ongoing phase II/III clinical study),” Biological E said in the statement Monday. The expected cost of Corbevax is Rs 145 excluding taxes. Every person is required to get two shots of vaccine scheduled 28 days apart. The government has already placed an order of over 5 crore doses which are most likely to be available by the end of February. 

“We are pleased with this significant development, which helps extend the reach of our vaccine to the age group of 12 to 18 years in our country. We truly believe that with this approval, we are even closer to finishing our global fight against the COVID-19 pandemic,” Biological E Managing Director Mahima Datla said in a statement. By far India has successfully vaccinated more than half of the population. The daily positivity rate in India is 1.24% and the weekly is 1.98%. Regular international flights are most likely to be resumed from 15th March. 

By TIS Staffer
the authorBy TIS Staffer

Leave a Reply